Global Nilotinib Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Nilotinib Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Nilotinib is a type of targeted cancer drug called a tyrosine kinase inhibitor (TKI).
Nilotinib report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Nilotinib market is projected to reach US$ 1200.7 million in 2029, increasing from US$ 1923 million in 2022, with the CAGR of -5.4% during the period of 2024 to 2029. Demand from Hospital and Drugs Store are the major drivers for the industry.
Tasigna, a targeted therapy used in the treatment of certain types of leukemia, is witnessing increasing demand. Factors driving market growth include the rising incidence of leukemia, advancements in precision medicine, and the efficacy of Tasigna in treating resistant forms of the disease. Key players in the market are investing in research and development to expand the indications of Tasigna and explore its potential in combination therapies. Additionally, strategic collaborations and regulatory approvals are contributing to market expansion. However, challenges such as high treatment costs and the availability of generic alternatives may impact market growth.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Nilotinib market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Novartis
Segment by Type
50mg
200mg
Other
Hospital
Drugs Store
Other
North America
the United States
Canada
Europe
Germany
France
UK
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Nilotinib market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Nilotinib, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Nilotinib industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Nilotinib in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Nilotinib introduction, etc. Nilotinib Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Nilotinib market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Nilotinib report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Nilotinib market is projected to reach US$ 1200.7 million in 2029, increasing from US$ 1923 million in 2022, with the CAGR of -5.4% during the period of 2024 to 2029. Demand from Hospital and Drugs Store are the major drivers for the industry.
Tasigna, a targeted therapy used in the treatment of certain types of leukemia, is witnessing increasing demand. Factors driving market growth include the rising incidence of leukemia, advancements in precision medicine, and the efficacy of Tasigna in treating resistant forms of the disease. Key players in the market are investing in research and development to expand the indications of Tasigna and explore its potential in combination therapies. Additionally, strategic collaborations and regulatory approvals are contributing to market expansion. However, challenges such as high treatment costs and the availability of generic alternatives may impact market growth.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Nilotinib market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Novartis
Segment by Type
50mg
200mg
Other
Segment by Application
Hospital
Drugs Store
Other
Segment by Region
North America
the United States
Canada
Europe
Germany
France
UK
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Nilotinib market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Nilotinib, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Nilotinib industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Nilotinib in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Nilotinib introduction, etc. Nilotinib Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Nilotinib market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.